Breaking News
Get 40% Off 0
😲 Missed the +20.8% surge in our stock strategy last month? Not again! Get premium insights Get 40% Off Now

Reckitt Benckiser, Indivior, ask London court to throw out Suboxone lawsuit

Published Nov 20, 2023 15:18 Updated Nov 20, 2023 16:18
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A pharmacist fills a Suboxone prescription at Boston Healthcare for the Homeless Program in Boston, Massachusetts January 14, 2013. REUTERS/Brian Snyder/File Photo
 
RKT
-0.47%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
INDV
-0.40%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Tobin

LONDON (Reuters) - Consumer goods giant Reckitt Benckiser and Indivior on Monday urged London's High Court to throw out a representative lawsuit over allegedly false marketing of opioid addiction treatment Suboxone.

London-listed drugmaker Indivior and Reckitt Benckiser, its parent until Indivior was spun off in 2014, are facing a claim brought on behalf of hundreds of investors potentially worth hundreds of millions of pounds.

Wirral Council in north-west England wants to bring a representative claim based on an alleged scheme to switch the market for Suboxone from tablets, which were about to lose patent protection in the U.S., to a sublingual film.

But Reckitt Benckiser and Indivior, which deny the allegations, want the representative case dismissed.

Wirral Council says that when Indivior was indicted in the U.S. in 2019, in one of the few corporate prosecutions related to the U.S. opioid addiction epidemic, the news wiped out over 550 million pounds ($685.9 million) of its market value.

It is seeking a declaration that Reckitt Benckiser and Indivior published false, misleading or incomplete information to the markets about the alleged scheme.

Investors could then bring their own "follow-on" damages lawsuits based on the court's findings, which the council says would be cheaper, less complicated and promote "shareholder redress and access to justice".

But Reckitt Benckiser and Indivior argue a representative lawsuit would just give claimants other than Wirral Council a "free ride" until liability is decided.

They also say Wirral Council and others have brought a separate lawsuit which would continue if the representative case is dismissed.

Indivior has agreed to pay out over $500 million this year alone to settle civil lawsuits brought by drug wholesalers, dozens of U.S. states and health plans in relation to Suboxone.

In 2020, the company also agreed to pay $600 million to resolve U.S. government allegations that it fraudulently promoted Suboxone.

Reckitt Benckiser had agreed to pay out $1.4 billion to resolve any potential criminal or civil liability in 2019.

Reckitt Benckiser's lawyers said on Monday that the settlement was reached without any admission of liability.

Reckitt Benckiser, Indivior, ask London court to throw out Suboxone lawsuit
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email